Scientists have found a cause for the frequent and damaging events in cancer cells’ genetic material where sections of individual chromosomes were broken at a number of points and reassembled wrongly, so entire sections were missing and others were duplicated or incorporated in a wrong orientation.
Tumours are helped in their development by mutating the most important cancer-prevention gene, p53, scientists from Melbourne have found. The study, published in Genes and Development, found that mutant p53 prevents the regular p53 protein from activating its natural defences, increasing the risk of the cancer spreading.
Scientists from Cancer Research UK in Cambridge have advanced research into liquid biopsies for brain tumours by detecting tumour DNA in the fluid around the spine and brain.
If you’ve been part of the GeoMx DSP Technology Access Program, then you’ll already know why this is so exciting. If you haven’t heard about it yet, then you should make sure you’re sitting down – yes it really is that exciting.
Given that Front Line Genomics was started after its founder’s father was diagnosed with Mesothelioma, it’s naturally a cause that we care passionately about. To that end we sat down with the Mesothelioma Cancer Alliance (MCA), an organisation dedicated to providing resources, information, and support to individuals suffering from mesothelioma and other asbestos-related diseases and their families, to find out more about the great work they do and the challenges they face every day.
AMP 2018: Decoding the Cancer Genome: Breakthrough AI Technology Quickly Identifies Actionable Mutations
Explosive advances in next-generation sequencing (NGS) have greatly improved the ability to identify actionable cancer mutations, both for solid and hematological malignancies, and sparked a new era of oncology care. But accurate analysis and proper interpretation of the complex genomic data produced by NGS remain key hurdles.
Every single cell in the human body could contain a cancer “kill code” set to destroy cells which become cancerous, a new study reported in Nature Communications. The study, conducted by Northwestern University in the US, found that cancer cannot become resistant to this code, making it a potentially incredibly effective treatment.
Researchers at the Stanford University School of Medicine and their collaborators at other institutions have identified a link between how proteins bind to our DNA and how cancer develops.
Genome Sequencing Found Feasible and Informative for Pediatric Cancer Treatment Findings Reported at ASHG 2018 Annual Meeting
Presenting author Scott Newman, PhD; Jinghui Zhang, PhD; and Kim Nichols, MD, along with an interdisciplinary team at St. Jude Children’s Research Hospital, studied 253 pediatric oncology patients with a variety of cancers.
Genomics England names Congenica as its Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service.
A new report from the University of Pennsylvania School of Veterinary Medicine has expanded what we know about the connection between myeloid-derived immunosuppressor cells (MDSCs) and aggressive disease. Their research has found that blocking the deltaNp63 protein on tumour cells which directs MDSCs to tumour and metastatic sites, or blocking the MDSCs themselves, reduces tumour growth and metastasis in a mouse model of triple-negative breast cancer (TNBC).
The 2018 Nobel Prize for Physiology or Medicine has been awarded to James Allison and Tasuku Honjo for their work on cancer immunotherapy.
ASCO checkpoint inhibitor battle between Merck and Roche highlights the pitfalls in directly comparing clinical trial results in the era of precision medicine.
Precision medicine is showing significant signs of success across tumour types.